重组人血管内皮抑制素联合化疗治疗晚期非小细胞肺癌近期疗效观察

Observation of early curative effect of homemade human rh-endostatin injection in combination with chemotherapy for advanced non-small cell lung cancer

目的观察重组人血管内皮抑制素注射液联合含铂化疗方案治疗晚期非小细胞肺癌(NSCLC)的客观疗效及安全性。方法18例Ⅲa～Ⅳ期NSCLC患者恩度TM(重组人血管内皮抑制素)注射液联合含铂化疗方案治疗2周期,其中恩度TM15mg静脉滴注14d,配合化疗一程为一周期,一周后重复。观察近期有效率、近期临床受益率、生活质量及毒副反应。结果近期有效率33.33%,近期临床受益率72.22%,生活质量有一定改善,毒副反应小。结论恩度注射液与含铂化疗方案联合应用治疗晚期非小细胞肺癌具有协同作用,可提高患者的近期疗效,改善患者的生活质量,未见明显的不良反应。

Objective To observe the objective effect and safety in the treatment of advanced non-small cell lung cancer(NSCLC) using Combination chemotherapy with homemade human rh-endostatin injection.Methods 18 cases with advanced NSCLC(stage Ⅲ a to IV) were administrated with combination rh-endostatin injection with chemotherapy including DDP for two cycle,which using rh-endostatin injection 15mg ivgtt.day 1～14 and chemotherapy a cycle,and repeating after a week.To observe early response rate(RR),clinical benefit r...